PaiDaKang Included in Medical Insurance: Pegbio (02565.HK) Ushers in Release of Differentiated Value

As star drugs such as semaglutide and tirzepatide continue to reshape the market's understanding of the glucose-lowering and weight-loss effects of GLP-1 drugs, domestic innovative pharmaceutical companies have also been stepping up their efforts in this track, and the GLP-1 market appears to no longer lack good drugs. However, on the other side of the continuously expanding market size, the phenomenon of some patients discontinuing medication due to factors such as gastrointestinal adverse reactions and treatment costs still persists. For patients with type 2 diabetes who require long-term blood glucose control, drugs not only need to be effective but also need to take into account tolerability, treatment convenience, and the affordability of long-term medication. These clinical needs that have not yet been fully met are providing new development space for GLP-1 innovative drugs with differentiated characteristics.